Table 1.
Maltonis mean IC50 values in a panel of human derived sarcoma and human normal mesenchymal cells
| Histotypea | Cell lineb | IC50 μM (± SE)c,f | Genetic alterationd | Doubling time (hours)e,f |
|---|---|---|---|---|
| RHABDOMYOSARCOMA |
RD/18 |
6.8 (± 2.1) |
Altered 11p15.5 chromosome |
22 ± 0.1 |
| |
SJ-RH4 |
5.6 (± 1.3) |
(2;13)(q35;q14) PAX3 FKHR |
25 ± 1.2 |
| |
SJ-RH30 |
9.9 (± 2.7) |
(2;13)(q35;q14) PAX3 FKHR |
26 ± 1.0 |
| OSTEOSARCOMA |
IOR/OS10 |
5.5 (± 1.3) |
Complex Karyotype |
30.4 ± 2.6 |
| |
IOR/OS9 |
8.6 (± 1.8) |
Complex Karyotype |
44.5 ± 2.4 |
| |
Saos-2 |
11.9 (± 3.1) |
Complex Karyotype |
36.1 ± 4.4 |
| |
Saos-2/DX580 |
39.3 (± 2.6) |
Complex Karyotype |
75.6 ± 5.7 |
| |
Saos-2/CDDP6ug |
43.3 (± 6.8) |
Complex Karyotype |
44.3 ± 4.1 |
| |
U-2OS |
12.5 (± 0.7) |
Complex Karyotype |
18.3 ± 0.2 |
| |
U-2OS/DX580 |
16.5 (± 0.4) |
Complex Karyotype |
45.3 ± 4.7 |
| |
U-2OS/CDDP4ug |
56.1 (± 1.4) |
Complex Karyotype |
38.6 ± 4.1 |
| EWING SARCOMA |
6647 |
3.1 (± 1.4) |
t(11;22)(q24;q12) EWSR1-FLI1 TYPE II |
29 ± 2.3 |
| |
LAP-35 |
11.6 (± 0.7) |
t(11;22)(q24;q12) EWSR1-FLI1 TYPE II |
48.6 ± 4.2 |
| |
SK-N-MC |
3.9 (± 0.5) |
t(11;22)(q24;q12) EWSR1-FLI1 TYPE I |
26.9 ± 0.5 |
| |
TC-71 |
2.6 (± 1.4) |
t(11;22)(q24;q12) EWSR1-FLI1 TYPE I |
14.9 ± 1.4 |
| |
TC/DOXO8 |
5.0 (± 0.1) |
t(11;22)(q24;q12) EWSR1-FLI1 TYPE I |
22.6 ± 2.8 |
| h-MSC |
MES1 |
>50 |
n.d. |
n.d. |
| |
MES2 |
>50 |
n.d. |
n.d. |
| DP-15 | >50 | n.d. | n.d. |
a Histotype: origin of the patient-derived cell line.
b cell line name.
c mean IC50 calculated over three idependent experiments ± SE.
d genetic alterations associated to the cell line.
e doubling time of the indicated cell line.
f IC50 values statistically correlate with cell doubling times (r = 0.59, p = 0.01, Pearson correlation test).
n.d. not determined.